Stephen S. Grubbs

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases

Andrew L. Himelstein, Jared C. Foster, James Khatcheressian et al. · JAMA · 2017 · 349 citations · Full text

The National Cancer Institute–American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and Recommendations

Andrea Denicoff, Worta McCaskill‐Stevens, Stephen S. Grubbs et al. · Journal of Oncology Practice · 2013 · 142 citations · Full text

Phase II study of recombinant alpha-2 interferon in resistant multiple myeloma.

J J Costanzi, M. Robert Cooper, J.H. Scarffe et al. · Journal of Clinical Oncology · 1985 · 107 citations

Recombinant Alpha-2 Interferon, Resistant Multiple Myeloma, Immunology +21

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)

Charles L. Shapiro, James P. Moriarty, Stacie B. Dusetzina et al. · Journal of Clinical Oncology · 2017 · 73 citations · Full text

Denosumab Sre Probabilities, Surgical Oncology, Cost-effectiveness Analysis +20

Use of the National Cancer Institute Community Cancer Centers Program Screening and Accrual Log to Address Cancer Clinical Trial Accrual

Diane St. Germain, Andrea Denicoff, Eileen Dimond et al. · Journal of Oncology Practice · 2014 · 59 citations · Full text